Illumina (ILMN) announced the launch of TruPath Genome. Illumina said: “TruPath Genome has been found to deliver unparalleled accuracy and resolution-even across so-called ‘dark regions’ of the genome-providing researchers with a more complete picture of genomic alterations implicated in genetic disease.” TruPath Genome delivers a whole genome workflow solution at a $395 USD list price.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina: Weak Backlog Support and Rising Competitive Pressures Undermine 2026 Outlook, Justifying Sell Rating
- Illumina price target lowered to $170 from $195 at Piper Sandler
- Illumina Earnings Call Highlights Clinical Growth Momentum
- Illumina price target raised to $137 from $132 at Baird
- Illumina price target raised to $135 from $120 at UBS